Dr Laura Llewellyn

Dr Laura Llewellyn

Institute of Cancer and Genomic Sciences
Early Drug Development Team Leader, Cancer Research UK Clinical Trials Unit (CRCTU)

Contact details

+44 (0) 121 415 8421
+44 (0) 121 414 3529
Cancer Research UK Clinical Trials Unit,
Institute of Cancer and Genomic Sciences,
University of Birmingham,
B15 2TT

Dr Laura Llewellyn (née Crack) is Early Drug Development Team Leader at the Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences at the University of Birmingham.


D.Phil. Clinical Immunology, University of Oxford, 2010.

MSc Biomedical Science with Medical Microbiology, Cardiff Metropolitan University, 2005.

BSc (Hons) Biology, University of Sheffield, 2004.


Laura Llewellyn graduated with a BS. (Hons) in Biology from the University of Sheffield in 2004. She then worked as an Executive Officer in the Chronic Illness and Community Health Branch of the Welsh Assembly Government. During this time she studied for an MSc in Biomedical Science with Medical Microbiology at Cardiff Metropolitan University, graduating in 2006. Following this she was awarded a fully funded Medical Research Council studentship to study for a D.Phil. at the University of Oxford, investigating the role of T cells in allergic eczema.

Laura joined the Early Drug Development (EDD) Team of the Cancer Research UK Clinical Trials Unit at the University of Birmingham in 2011, coordinating academic and commercially sponsored early phase trials in a variety of solid tumours. In 2012 she was promoted to Senior Trial Coordinator within the EDD team, increasing her involvement in the development and strategic direction of the early phase solid tumour portfolio.

In 2013 Laura was appointed as the EDD Team leader and has helped to secure an award to coordinate the National Lung Matrix Trial, a core component of CR-UK’s Stratified Medicine Programme phase 2 which aims to bring personalised medicine to advanced lung cancer patients. She is currently studying for a Post-graduate diploma in Clinical Oncology, having been awarded a CR-UK centre scholarship in 2012.


Phase I and II Clinical Trials– BMedSci

Financial and Resource Aspects of a Research Project - MSc Clinical Science (Blood Science)


Laura Llewellyn has contributed to the design, set-up and management of several academic trials such as:

  • SCART – Phase I/II trial of MEK Inhibition in Kaposi’s sarcoma
  • AdUP - Phase I trial of recombinant adenovirus in locally recurrent prostate cancer
  • National Lung Matrix Trial - Multi-drug, genetic marker directed, non-comparative multi-arm Phase II trial in non-small cell lung cancer (NSCLC)
  • BUTEO – phase II trial of anti-VAP-01 in Primary Sclerosing Cholangitis


Crack L, Jones, L, Malavige GN, Patel V and Ogg GS (2012). Human anti-microbial peptides LL-37 and human β-defensin-2 reduce viral load in VZV infected keratinocytes. Clinical and Experimental Dermatology 37 (5): 534-43.

Crack L, McPherson T, Chan HW and Ogg GS (2012). Identification of an immunodominant region of the major house dust mite allergen Der p 2 presented by common HLA alleles. Clinical and Experimental Dermatology 37 (3): 266-76.

Crack L, Chan HW, McPherson T and Ogg GS (2011). Phenotypic Analysis of Perennial Airborne Allergen-specific CD4+ T cells in Atopic and Non-atopic Individuals. Clinical and Experimental Allergy (Editor’s Choice) 41 (11): 1555-67.

McPherson T, Aslam A, Crack L, Chan H, Jones L and Ogg GS (2010). Frequencies of circulating allergen specific T cells temporally associate with longitudinal changes in the severity of cutaneous atopic disease. Clinical and Experimental Dermatology. 35 (7): 786-88.

Malavige GN, Rohanachandra LT, Jones L, Crack L, Perera M, Fernando N, Guruge D, Ogg GS (2010). IE-63-specific T cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies. British Journal of Cancer. 102 (4): 727-30.

McPherson T, Sherman V, Aslam A, Crack L, Lloyd-Lavery A, Chan H, Jones, L, Ardern-Jones M and Ogg GS (2010). Filaggrin null mutations associate with increased frequencies of allergen-specific CD4+ Th2 cells in patients with atopic eczema. British Journal of Dermatology. 163 (3): 544-49.